Eslam Abd Elshafi Mohamady Tabl
Asst. Professor
Prospective Randomized Evaluation of Local Injection of Allogeneic Growth Factors in Plantar Fasciitis
Foot and Ankle International • 2020
Publication Information
Authors
Mahmoud Kandil ; Eslam A Tabl ; Adel Samy
Keywords
plantar fasciitis, allogeneic growth factors, lyophilized human platelet growth factors (L-GFs)
Journal
Foot and Ankle International
Publisher
SAGE Publications
Volume
1
Issue
1
Pages
1-7
publication.type
International
Paper Link
Open Link
Supplementary Materials
Eslam Abd Elshafi Mohamady Tabl_paper.docx
Abstract
Background:
The aim of this study was to evaluate the efficacy and safety of injection of allogeneic growth factors in patients with plantar fasciitis.
Methods:
This study included 150 patients who were randomly divided into 2 equal groups; the patients were locally injected with allogeneic growth factors (GFs) (treatment group) or with saline 0.9% (control group). The patients were assessed using visual analog scale (VAS) and Foot Function Index–Revised short form (FFI-Rs) scores preinjection and 1, 3, 6, and 12 months postinjection. The patients were questioned about their satisfaction. Any adverse effects were recorded.
Results:
At baseline, there was no significant difference between both groups regarding the mean VAS and FFI-Rs scores. At 3-month follow-up, the reduction in mean VAS score was 87% in the treatment group and 55% in the control group (P < .001), and the reduction in mean FFI-Rs score was 62 …
The aim of this study was to evaluate the efficacy and safety of injection of allogeneic growth factors in patients with plantar fasciitis.
Methods:
This study included 150 patients who were randomly divided into 2 equal groups; the patients were locally injected with allogeneic growth factors (GFs) (treatment group) or with saline 0.9% (control group). The patients were assessed using visual analog scale (VAS) and Foot Function Index–Revised short form (FFI-Rs) scores preinjection and 1, 3, 6, and 12 months postinjection. The patients were questioned about their satisfaction. Any adverse effects were recorded.
Results:
At baseline, there was no significant difference between both groups regarding the mean VAS and FFI-Rs scores. At 3-month follow-up, the reduction in mean VAS score was 87% in the treatment group and 55% in the control group (P < .001), and the reduction in mean FFI-Rs score was 62 …